Severe hemophilia A: Research & Drug Discovery Data

Drug discovery

drug

With orphan designation

Overview

Severe Hemophilia A is an X-linked bleeding disorder characterized by factor VIII levels <1% of normal, resulting in spontaneous bleeding into joints, muscles, and soft tissues. Lifelong management focuses on preventing/treating bleeds through factor replacement or non-factor therapies. Complications include chronic arthropathy, inhibitor development, and substantial quality-of-life impairments [1][6][11][12].

Population

Affects ~1 in 5,000 male births [7][12]; >50% of US hemophilia A cases are severe [12].
Inhibitors develop in ~20-30% of patients, complicating treatment [6][8].

Burden

Annual healthcare costs exceed $600,000 for severe cases, driven by factor replacement [14][19].
40-70% of adults experience chronic pain; 50% use opioids long-term [5][16].
Severe cases show 9–12% lower health-related quality-of-life scores vs moderate disease [4][14].

Therapies

Prophylaxis: Regular FVIII infusions (plasma-derived or recombinant) to maintain levels ≥1% [1][18].
Non-factor therapies: Subcutaneous emicizumab (bispecific antibody mimicking FVIII) reduces bleed frequency [3][6].
Immune tolerance induction: High-dose FVIII regimens for inhibitor eradication [8].

Categories: rare genetic diseases, rare hematological diseases

Research Papers

3,169 drug discovery papers related to Severe hemophilia A, with 3 first-in-class and 8 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:

2026-07-09 | Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)

This study is for young children with severe hemophilia A who have previously not been treated with BAX855 or other FVIII concentrates.The main aim of the study is to check for side effects from treatment with BAX855. This includes the buildup of antibodies against FVIII which may stop BAX855 from working properly. Another aim is to learn how well BAX855 controls bleeding.In this study, the children can receive BAX855 either as preventative treatment (prophylaxis), or as needed to treat bleeding (on-demand).In case a participant develops antibodies, treatment will be provided as part of the study.

Open article ↗

2026-07-09 | A Phase 3, Prospective, Multicenter, Open-label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (ADYNOVATE) Administered for Prophylaxis and Treatment of Bleeding in Chinese Previously Treated Patients With Severe Hemophilia A (FVIII <1%)

The main aim of the study is to determine how well Adynovate works to decrease bleeding in previously treated Chinese men and boys with severe hemophilia A when given prophylactically.Participants will be treated with Adynovate twice a week for 26 weeks or until participants have received 50 days of treatment with Adynovate (whichever takes longer). Participants will need to visit their study clinic several times during their participation.

Open article ↗

2026-07-09 | A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A

The study purpose is:* To assess the incidence of FVIII inhibitory antibodies during 6 months of twice weekly prophylactic treatment with BAX 855 or 50 exposure days (EDs), whichever occurs last.* To compare pharmacokinetic (PK) parameters to ADVATE.* To assess hemostatic efficacy in prophylaxis and the treatment of bleeding episodes.* To evaluate safety and immunogenicity.

Open article ↗

2026-07-09 | Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)

Open article ↗

2026-07-09 | A Phase 3, Prospective, Multicenter, Open-label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (ADYNOVATE) Administered for Prophylaxis and Treatment of Bleeding in Chinese Previously Treated Patients With Severe Hemophilia A (FVIII <1%)

Open article ↗

2026-07-09 | A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A

Open article ↗

Access all drug discovery articles and probability of success in trials forecasts:

Request access

Drug Discovery Landscape

1 orphan drug designation for Severe hemophilia A.

Drug	Therapy type	Regulator	Orphan designation	Approval	Sponsor
an autologous gene therapy consisting of CD34+ hematopoietic stem and progenitor cells transduced ex-vivo with the CD68-ET3-LV lentiviral vector	gene therapies	FDA	2026-04-12	—	Expression Therapeutics LLC

Severe hemophilia A

Severe hemophilia A

Severe hemophilia A

Overview

Population

Burden

Therapies

Categories: rare genetic diseases, rare hematological diseases

Research Papers

2026-07-09 | Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)

2026-07-09 | A Phase 3, Prospective, Multicenter, Open-label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (ADYNOVATE) Administered for Prophylaxis and Treatment of Bleeding in Chinese Previously Treated Patients With Severe Hemophilia A (FVIII <1%)

2026-07-09 | A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A

2026-07-09 | Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)

2026-07-09 | A Phase 3, Prospective, Multicenter, Open-label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (ADYNOVATE) Administered for Prophylaxis and Treatment of Bleeding in Chinese Previously Treated Patients With Severe Hemophilia A (FVIII <1%)

2026-07-09 | A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A

Drug Discovery Landscape

Updated: Aug 13, 2026